JP2023082086A5 - - Google Patents

Download PDF

Info

Publication number
JP2023082086A5
JP2023082086A5 JP2023052465A JP2023052465A JP2023082086A5 JP 2023082086 A5 JP2023082086 A5 JP 2023082086A5 JP 2023052465 A JP2023052465 A JP 2023052465A JP 2023052465 A JP2023052465 A JP 2023052465A JP 2023082086 A5 JP2023082086 A5 JP 2023082086A5
Authority
JP
Japan
Prior art keywords
crystalline form
powder
ray diffraction
pharmaceutical composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023052465A
Other languages
English (en)
Japanese (ja)
Other versions
JP7763203B2 (ja
JP2023082086A (ja
Filing date
Publication date
Priority claimed from JP2019538551A external-priority patent/JP7253491B2/ja
Application filed filed Critical
Publication of JP2023082086A publication Critical patent/JP2023082086A/ja
Publication of JP2023082086A5 publication Critical patent/JP2023082086A5/ja
Application granted granted Critical
Publication of JP7763203B2 publication Critical patent/JP7763203B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023052465A 2016-09-29 2023-03-28 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用 Active JP7763203B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201610866253.6 2016-09-29
CN201610866253 2016-09-29
JP2019538551A JP7253491B2 (ja) 2016-09-29 2017-09-29 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用
PCT/CN2017/104506 WO2018059556A1 (zh) 2016-09-29 2017-09-29 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019538551A Division JP7253491B2 (ja) 2016-09-29 2017-09-29 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用

Publications (3)

Publication Number Publication Date
JP2023082086A JP2023082086A (ja) 2023-06-13
JP2023082086A5 true JP2023082086A5 (enExample) 2023-07-28
JP7763203B2 JP7763203B2 (ja) 2025-10-31

Family

ID=61763329

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019538551A Active JP7253491B2 (ja) 2016-09-29 2017-09-29 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用
JP2023052465A Active JP7763203B2 (ja) 2016-09-29 2023-03-28 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019538551A Active JP7253491B2 (ja) 2016-09-29 2017-09-29 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用

Country Status (17)

Country Link
US (3) US11053224B2 (enExample)
EP (1) EP3502105B8 (enExample)
JP (2) JP7253491B2 (enExample)
KR (1) KR102289684B1 (enExample)
CN (1) CN108884080B (enExample)
AU (1) AU2017336889B2 (enExample)
CA (2) CA3035124C (enExample)
EA (1) EA201990688A1 (enExample)
ES (1) ES2914294T3 (enExample)
IL (2) IL265266B2 (enExample)
MY (1) MY194364A (enExample)
PH (1) PH12019500681A1 (enExample)
PL (1) PL3502105T3 (enExample)
SG (1) SG11201901962QA (enExample)
TW (1) TWI647224B (enExample)
WO (1) WO2018059556A1 (enExample)
ZA (1) ZA201901717B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201901962QA (en) * 2016-09-29 2019-04-29 Equinox Sciences Llc Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3171563A1 (en) 2020-03-25 2021-09-30 Charles D. Blizzard Ocular implant containing a tyrosine kinase inhibitor
SI4210682T1 (sl) 2020-09-14 2026-07-31 EyePoint, Inc. Bioerozibilni očesni vložek za dovajanje zdravil in terapevtska metoda
CN117157294A (zh) * 2021-03-16 2023-12-01 怡诺安有限公司 作为蛋白激酶抑制剂的杂环化合物的结晶形式
JP7138982B1 (ja) 2021-09-24 2022-09-20 東海物産株式会社 アンセリンの結晶及びその製造方法
IL315331A (en) 2022-03-11 2024-10-01 Eyepoint Pharmaceuticals Inc A method of preventing age-related ocular degeneration by providing a drug entry mechanism into the eye
US20250186398A1 (en) 2022-03-11 2025-06-12 EyePoint Pharmaceuticals, Inc. Continuous dosing regimen for treatment of a condition of the eye
TW202345804A (zh) 2022-03-11 2023-12-01 美商視點製藥有限公司 治療濕性老年黃斑部病變(Wet Age-related Macular Degeneration)之方法
JP2026520094A (ja) 2023-04-11 2026-06-22 オキュラ セラピューティクス,インコーポレイテッド アキシチニブ多形ivを含む眼科インプラント
CN117143083B (zh) * 2023-08-30 2026-02-27 沈阳药科大学 VEGFR抑制剂Vorolanib的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508953A (ja) * 2001-10-10 2005-04-07 スージェン・インコーポレーテッド キナーゼ阻害剤としての3−[4−(置換ヘテロサイクリル)−ピロール−2−イルメチリデン]−2−インドリノン誘導体
WO2008033562A2 (en) * 2006-09-15 2008-03-20 Xcovery, Inc. Kinase inhibitor compounds
US20110026367A1 (en) * 2007-05-07 2011-02-03 Baumer Electric Ag Acoustic Transducer
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
WO2009128083A1 (en) * 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
CN102066362B (zh) 2008-05-23 2014-07-30 上海医药工业研究院 二氢吲哚酮衍生物
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2264027A1 (en) 2009-05-27 2010-12-22 Ratiopharm GmbH Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
CN106928114B (zh) * 2015-12-31 2020-07-28 韶远科技(上海)有限公司 含有脲基的环状手性氨基类化合物及其可放大工艺和用途
SG11201901962QA (en) * 2016-09-29 2019-04-29 Equinox Sciences Llc Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof

Similar Documents

Publication Publication Date Title
JP2021530565A5 (enExample)
JP2020512316A5 (enExample)
JP2024521412A5 (enExample)
JP2010516681A5 (enExample)
CN115698019A (zh) 用作parp抑制剂的吲哚并七元酰肟类似物的结晶及其制备方法
CN1227233C (zh) 纯晶形的5-氯-3-(4-甲磺酰基苯基)-6′-甲基-[2,3′]联吡啶及其合成方法
JP2009521414A5 (enExample)
JP2023002516A5 (enExample)
JP2022183220A5 (enExample)
JP2005503386A5 (enExample)
JP2023036708A5 (enExample)
JP2023511105A5 (enExample)
JP2019504103A5 (enExample)
JP2022511800A5 (enExample)
JP2013538849A5 (enExample)
JP2022512482A5 (enExample)
JP2019516749A5 (enExample)
JP2007532560A5 (enExample)
RU2015134420A (ru) Кристаллические формы { [1-циано-5-(4-хлорофеноксид)-4-гидроксид-изохинолин-3-карбонил]-амино} -уксусной кислоты
AU2001264804A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
CN102964384B (zh) 阿德福韦酯没食子酸共晶及其制备方法和组合物
JP2024505063A5 (enExample)
JP2024514090A5 (enExample)
JP2025102940A5 (enExample)
JP2023521411A5 (enExample)